{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-036941","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.086555+00:00","generated_at":"2026-06-04T09:45:33.143650+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Milestone Pharma reports Q4 net loss of $13.6M; on track to resubmit NDA for etripamil in PSVT early Q2 2024","bullets":["Net loss of $13.6M in Q4 2023, full year net loss $59.7M; Q4 revenue was $0 (vs $3.5M in Q4 2022).","Cash and equivalents $66M as of Dec 31, 2023; March 2024 offering raised ~$32.4M net, extending cash runway into 2026.","Plans to resubmit NDA for etripamil in PSVT early Q2 2024 after Type A meeting with FDA resolved RTF items.","FDA reiterated guidance for AFib-RVR Phase 3 pathway contingent on PSVT NDA approval; End of Phase 2 meeting expected mid-2024.","R&D expense fell to $5.5M in Q4 (vs $10.6M) as Phase 3 studies completed; commercial expense rose to $5.0M (vs $2.6M) for launch prep."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-036941","json":"https://secwatch.observer/filing/0001104659-24-036941.json","markdown":"https://secwatch.observer/filing/0001104659-24-036941.md","text":"https://secwatch.observer/filing/0001104659-24-036941.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924036941/0001104659-24-036941-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924036941/tm249389d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:45:33.143650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f61b7aae861523304e7d92242fe687b5de584530","claim":"Milestone Pharmaceuticals Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_excerpt":"On March 21, 2024, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924036941/0001104659-24-036941-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}